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Abstract
Background: Pre-exposure prophylaxis (PrEP) trials using tenofovir-based regimens have demonstrated that high levels of
adherence are required to evaluate efficacy; the incorporation of objective biomarkers of adherence in trial design has been
essential to interpretation, given the inaccuracy of self-report. Antiretroviral measurements in scalp hair have been useful as
a marker of long-term exposure in the HIV treatment setting, and hair samples are relatively easy and inexpensive to collect,
transport, and store for analysis. To evaluate the relationship between dose and tenofovir concentrations in hair, we
examined the dose proportionality of tenofovir in hair in healthy, HIV-uninfected adults.
Methods: A phase I, crossover pharmacokinetic study was performed in 24 HIV-negative adults receiving directly-observed
oral tenofovir tablets administered 2, 4, and 7 doses/week for 6 weeks, with a $3-week break between periods. Small
samples of hair were collected after each six-week period and analyzed for tenofovir concentrations. Geometric-mean-ratios
compared levels between each pair of dosing conditions. Intensive plasma pharmacokinetic studies were performed during
the daily-dosing period to calculate areas-under-the-time-concentration curves (AUCs).
Results: Over 90% of doses were observed per protocol. Median tenofovir concentrations in hair increased monotonically
with dose. A log-linear relationship was seen between dose and hair levels, with an estimated 76% (95% CI 60–93%)
increase in hair level per 2-fold dose increase. Tenofovir plasma AUCs modestly predicted drug concentrations in hair.
Conclusions: This study found a strong linear relationship between frequency of dosing and tenofovir levels in scalp hair.
The analysis of quantitative drug levels in hair has the potential to improve adherence measurement in the PrEP field and
may be helpful in determining exposure thresholds for protection and explaining failures in PrEP trials. Hair measures for
adherence monitoring may also facilitate adherence measurement in real-world settings and merit further investigation in
upcoming PrEP implementation studies and programs.
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exposure prophylaxis (PrEP), where at-risk HIV uninfected
individuals take antiretroviral medications daily to prevent
infection, has been demonstrated in several recent trials. The
iPrEx study demonstrated that daily administration of emtricita-

Introduction
Recent studies have provided new hope for effective HIV
biomedical prevention strategies [1–4]. The efficacy of pre-
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temperature prior to analysis and shipped without biohazard
precautions.
To widely employ hair as a biological marker of drug exposure
in HIV prevention settings, the relationship between different
dosing strategies and drug concentrations in this matrix must be
established. Moreover, individual variation in pharmacokinetic
(PK) parameters (e.g. plasma oral clearance measured as areasunder-the-concentration-time-curve or AUCs) can contribute to
variability of antiretroviral drug levels in various compartments
[26], so the effect of these parameters on hair drug concentrations
must be determined. We performed a phase I randomized
crossover study with the objective of examining the impact of
varying dosing patterns of oral TDF (2, 4 and 7 doses per week
using directly observed dosing) and individual plasma AUCs on
TFV concentrations in hair in healthy, HIV-negative adults.
These dosing frequencies were chosen to represent low, moderate,
and high adherence to PrEP. Furthermore, modeling studies
suggest TFV-DP levels achieved with these dosing patterns were
associated with increasing levels of PrEP efficacy [27]. In this
study, we found a strong relationship between dose and hair levels
of TFV, paving the way for further study of hair measures as an
adherence monitoring tool in PrEP trials and implementation
projects.

bine/tenofovir disoproxil fumarate (FTC/TDF) PrEP decreased
HIV-1 acquisition in men who have sex with men [2]. The
Partners PrEP trial and Botswana TDF2 study subsequently
verified and extended these findings in serodiscordant couples and
seronegative heterosexual adults respectively [3,4]. Most recently,
a trial in HIV-uninfected injection drug users (IVDU) in Thailand
showed a reduction in HIV incidence with the use of daily
tenofovir [5]. Cumulative data from these trials led to the approval
of FTC/TDF as PrEP for uninfected individuals at risk of HIV
infection by the Food and Drug Administration [6] and/or the
development of interim guidance for clinicians prescribing PrEP in
different populations [7–9].
Importantly, several trials have highlighted the critical relationship between adherence and PrEP efficacy. For example, the
efficacy of FTC/TDF in iPrEx rose from 44% overall to an
estimated 92% among those with detectable blood drug levels [2].
Furthermore, two large PrEP trials in sexually active African
women [10,11] were unable to demonstrate significant efficacy of
daily FTC/TDF in reducing HIV acquisition, likely due in large
part to low adherence to study drug.
Incorporating measures of drug exposure as biomarkers of PrEP
adherence has been critical to interpreting PrEP trials. In iPrEx,
although mean adherence by self-report was 95%, drug was
detected in only 8% of seroconverters compared with 54% of
matched active-arm controls who remained uninfected [2]. Selfreported adherence was similarly high in both FEM-PrEP [10]
and VOICE [11], but random plasma tenofovir (TFV) levels
among women on active drug revealed target ($10 nanograms per
milliliter) or detectable TFV concentrations in only 26% and 29%
of women, respectively. The limitations of self-report and other
commonly used adherence measures in HIV treatment monitoring
are well-described [12], and self-reported adherence may be
particularly inaccurate in clinical trials [13]. Biomarkers of drug
exposure can serve as surrogates of adherence because nonadherence is the most frequent cause of low drug levels.
Pharmacologic parameters may be especially critical to monitor
in HIV-negative individuals on antiretroviral prophylaxis since
HIV viral loads cannot serve as indicators of adherence in
noninfected persons.
Due to TFV’s extended intracellular half-life (,150 hours) [14],
an ideal adherence biomarker would reflect average drug exposure
over several weeks to months. Single plasma concentrations, which
represent only a small window of exposure (dosing in the last few
days) [15–17], are subject to significant day-to-day variation [15]
and ‘‘white-coat’’ effects [18,19] and are imperfect indicators of
exposure. As the concentration of drugs in hair reflects uptake
from the systemic circulation over an extended time window
(weeks to months) [20,21], hair analysis provides an advantage
over plasma monitoring in assessing average drug exposure over a
longer period of time. We have demonstrated that hair concentrations of antiretrovirals (ARVs) are the strongest independent
predictor of virologic success in large prospective cohorts of HIVinfected patients [22–25]. Analyzing antiretroviral levels in hair
may be a promising approach to objectively quantify adherence to
PrEP regimens as well. Although the measurement of intracellular
tenofovir diphosphate (TFV-DP) concentrations in peripheral
blood mononuclear cells (PBMCs) has been incorporated into
previous PrEP trials as a long-term measure of exposure, hair
levels may provide feasibility advantages in the field since methods
to process, isolate and count PBMCs are costly, technically
challenging, and difficult to institute widely. Unlike phlebotomy,
hair collection is noninvasive and does not require specific skills,
refrigeration, or sterile equipment. Hair can be stored at room
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Methods
Study Design and Participant Selection
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
STRAND was an open-label, randomized, three-period PK
study conducted between October 2009 and March 2011 at the
University of California San Francisco (UCSF) Clinical Research
Center and the San Francisco Department of Public Health
(SFDPH) Bridge HIV research clinic. To facilitate directly
observed dosing, participants were recruited from UCSF (students,
staff, and faculty) and from neighborhoods adjoining SFDPH.
Tablets of TDF (300 milligrams, mg) were provided by Gilead
Sciences (Foster City, CA). As several PrEP trials were evaluating
TDF alone as a PrEP agent [3,5,28] and no significant
pharmacokinetic interactions have been observed between tenofovir and emtricitabine [29], TDF tablets alone were chosen for
evaluation to minimize potential toxicity to healthy subjects in this
study. All subjects provided written informed consent prior to
study procedures and the study was approved by the UCSF
Committee on Human Research.
Eligible subjects were healthy male or female volunteers age 18
or older without serious or active medical conditions. Participants
were all HIV-negative based on HIV rapid antibody testing and
were hepatitis B surface antigen negative at enrollment. Enrolled
participants could not be on nephrotoxic agents, had to have an
estimated creatinine clearance $60 mL/min, serum creatinine
levels below the upper limit of normal, urine dipstick tests that
were negative or trace positive for glucose and protein, adequate
hepatic and hematologic function, and negative urine pregnancy
tests (for women). Female volunteers were required to use effective
contraception during the study.
All participants had to be willing to undergo directly observed
dosing (DOT), provide personal cell phone numbers for unobserved modified DOT (mDOT) visits, have dark (brown or black)
hair (to minimize interindividual variability in this proof-ofconcept study), a minimum occipital scalp hair length of 3
centimeters (cm), and not have used hair dyes or hair permanent
products in the past 3 months. Participants at high risk of HIV
2
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to 0.400 ng/mg hair, with a lower limit of quantitation at
0.002 ng/mg [34,35].
Plasma was collected in EDTA tubes for drug concentration
measurement for the intensive pharmacokinetic studies. Plasma
was analyzed for TFV via standard techniques of LC/MS/MS
[36]. The linearity of the concentration curves is in the range of 10
to 1000 ng/milliliter (mL), and the lower limit of quantification is
10 ng/mL.

infection, including those reporting injection drug use (IDU);
vaginal or anal intercourse with an HIV-positive partner, IDU
partner, or with more than 4 partners of the opposite sex; and/or
transactional sex in the prior 6 months were excluded.

Study Visit and Dosing Procedures
Subjects were randomly assigned to one of 6 dosing sequences
and completed three 6-week dosing periods of 2, 4 and 7 doses per
week, with a break of at least 3 weeks between periods (Figures 1
and 2). Based on an average hair growth rate of 1 centimeter per
month [30], a minimum of 3-weeks was chosen for the washout
period. Each sequence arm included both sexes equally for a total
of 12 male and 12 female participants. The 2 doses/week were
taken on Tuesday and Wednesday, and the 4 doses/week on
Monday, Tuesday, Thursday, and Friday. All scheduled doses on
Monday to Friday were directly observed by study staff, and
weekend doses were confirmed by text messaging or phone using
previously-described mDOT procedures [31,32]. A one-week
supply of back-up medication was provided for participants unable
to complete a directly-observed dose; these doses were confirmed
via phone or text message at dosing. Dosing visits occurred at
UCSF, SFDPH, or another location per participant convenience.
Participants returned to the clinic for follow-up at a start, midpoint (after 3 weeks of dosing), and end-point (at the end of each 6
week dosing period) visit for safety and adverse event monitoring,
symptom-directed physical exams, and rapid HIV testing.
At enrollment and end-point visits, approximately 150–200
strands of scalp hair were collected; additionally, a similar number
pubic hair strands were collected on an opt-in basis. After 4 weeks
of dosing during the 7 doses/week period (at steady state for
plasma TFV), participants were admitted to the UCSF Clinical
Research Center for intensive 24-hour plasma PK evaluations to
calculate individual PK parameters (plasma AUC for oral
clearance and Cmax). The participant’s usual diet was ascertained
prior to the PK visit, and simulation of the usual diet was
undertaken during PK sampling. An initial blood level was drawn
(called the ‘‘0’’ timepoint) prior to an observed dose of TFV,
followed by blood collection at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10,
12, 16, and 24 hours post-dose for measurement of TFV plasma
concentration. Concentrations could not be measured for one
participant at the 0.5 hour time and another participant at the
1.5 hour time; these were interpolated by fitting quadratic
functions to the log-concentrations using the two previous and
two subsequent times.

Statistical Analyses
All analyses were conducted using SAS (Version 9.2, SAS
Institute, Cary, NC) and Stata (Version 12.1, College Station,
TX). The primary outcome variable was concentration of TFV in
hair at each end-point visit. Median drug levels with 95%
confidence intervals (CIs) were calculated, and geometric mean
ratios with 95% CIs were used to compare levels between each
pair of dosing conditions. We used geometric means to avoid
overweighting large ratios and to match the logarithmic transformation used for the multivariate modeling. Spaghetti plots were
used to depict drug levels for each participant, with each line
representing an individual. The chosen sample size (n = 24) was
not based on formal power considerations, but was feasible and
expected to provide useful new information about typical
relationships between TDF dosing and drug concentrations, as
well as a preliminary assessment of how well hair levels could
distinguish between daily versus intermittent dosing.
Linear mixed models with random intercepts were used for
multivariable analyses of predictors of logarithmically transformed
hair levels. Plasma AUC0–24, a measure of the subject’s oral
clearance (dose*F/CL), was calculated using the linear-log
trapezoidal method, and Cmax was defined as the largest observed
TFV concentration in plasma over the 24 hours. The primary
predictor variables were dosing condition (2, 4, and 7 dose/week),
log-transformed plasma AUC, and log-transformed Cmax. We
examined linearity assumptions for continuous predictors by
adding quadratic terms to the models.

Results
Sociodemographics, Safety, and Dosing:
Twenty-four participants met eligibility criteria and were
enrolled (Figure 1). Demographics and baseline data for the 23
participants who provided one or more hair samples are shown in
Table 1.
There were 167 adverse events (AEs) reported during the study,
with each participant reporting at least 1 AE. Most AEs were
either mild, grade 1 (128 events, 76%) or moderate, grade 2 (37
events, 22%). The most commonly reported AEs were headache
(54%), upper respiratory infection (38%), nausea (29%), abdominal gas (17%), soft/loose stools (17%), and fatigue (17%). Only
one participant experienced a grade 3 AE (traumatic jaw fracture)
and one experienced a grade 4 AE (metastatic breast cancer), both
adjudicated as unrelated to study drug. Four participants withdrew
before completing all study procedures: one after the first TDF
dose due to a grade 2 hypersensitivity reaction (urticarial rash with
tongue tingling) occurring prior to PK data collection, one before
completing the 4 and 7 doses/week periods due to headaches, one
before completing the 2 doses/week period due to use of postexposure prophylaxis and elevated pancreatic enzymes, and one
before completing the 7 doses/week period due to the new cancer
diagnosis described above.
Over 90% of doses were observed according to protocol: 249/
267 (93%) doses in the 2 doses/week arm, 473/517 (91%) doses in
the 4 doses/week arm, and 773/856 (90%) in the 7 doses/week

Sample Collection and Processing
Several small thatches of hair (,150–200 strands) were cut as
close as possible to the scalp in the occipital region and/or pubic
region, and the distal portion labeled [22]. The proximal section of
the scalp or pubic hair sample (about 1.5 cm) was cut down and
chopped to 1–2 mm length segments with scissors and 5 mg were
weighed, processed and analyzed using liquid chromatography/
tandem mass spectrometry (LC/MS-MS). The tenofovir in the cut
hair sample was extracted with 50% methanol/water containing
1% trifluroacetic acid, 0.5% hydrazine dihydrochloride, and
internal standard in a 37uC shaking water bath overnight
(.12 hours) and then analyzed by a modified LC-MS/MS
method [33]. The relative error (%) and precision (coefficients of
variation (CV)) for spiked quality control hair samples at low,
medium and high concentrations were all ,15% (CV of 10.5%,
8.4%, and 6.0%, respectively). Each sample was analyzed once
due to the limited number of clinical hair samples. The method to
analyze TFV in hair was validated from 0.002 nanograms (ng)/mg
PLOS ONE | www.plosone.org
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Figure 1. CONSORT flowchart for STRAND study.
doi:10.1371/journal.pone.0083736.g001

(25%) doses during the 2 doses/week period, and another
participant missed 4/36 (11%) doses in the 4 doses/week period.

arm. Of these 1495 doses observed on protocol, 82% were DOT
and 18% were mDOT visits. An additional 130 (7.9%) doses were
taken from participants’ back-up medication supplies (confirmed
via phone/text message). Two participants were unable to attend
several consecutive DOT visits during their 7 doses/week period
due to travel; all 31 of these doses were confirmed on time via
phone or text. Combining per protocol doses and confirmed doses
from back-up supplies, 1624/1640 (99%) of expected doses were
taken according to prescribed schedules Overall, 55/67 (82%) of
dosing periods had 100% on-time completion rates, and only 2
periods had ,90% completion: one participant missed 3/12

PLOS ONE | www.plosone.org

TFV concentrations in hair
Median TFV levels in scalp hair increased monotonically from
2 to 4 to 7 doses/week (Table 2). There was minimal overlap in
TFV hair concentrations between 2 versus 7 doses/week, with
some overlap between the 2 versus 4 and 4 versus 7 doses/week
dosing periods. The geometric mean ratios were close to the ratios
of the doses: 4 versus 2 doses/week averaged 1.76 (versus 2.0 ratio
of doses); 7 versus 4 doses/week averaged 1.60 (versus 1.75 ratio of

4
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Figure 2. Dosing scheme for the STRAND Study.
doi:10.1371/journal.pone.0083736.g002

variation were 0.27 for hair at 2 doses/week, 0.34 at 4 doses/week,
and 0.25 at 7 doses/week.
In a model with log(doses per week) and log(AUC) as predictors,
a log-linear relationship was seen between doses per week and
TFV scalp hair level, with an estimated 76% (95% CI 60–93%,
p,0.0001) increase in hair level per 2-fold dose increase. Adding a
random dose effect to this model estimated minimal interindividual variability in dose effect (estimated random effect
variance of zero), suggesting very similar dose effects across most
subjects. TFV plasma AUCs, ranging from 1210 to 5610 ng6h/
mL, were a moderate predictor of TFV hair level, with a 23%
increase in hair level per 2-fold increase in AUC (p = 0.035).

doses); 7 versus 2 doses/week averaged 2.85 (versus 3.5 ratio of
doses).
Figure 3 depicts the scalp hair TFV concentrations for the 2, 4,
and 7 doses/week periods for each individual. A concentration of
TFV in hair of 0.021 ng/mg reliably distinguished between 2
versus 7 doses/week (before rounding, all levels for 2 doses/week
were ,0.021 ng/mg, and all levels for 7 doses/week were
.0.021 ng/mg). Tenofovir hair concentrations were higher for
7 versus 4 doses/week and 4 versus 2 doses/week in all but 3
participants (Table 3). These 3 participants did not have fewer
observed doses or other signs of altered adherence. Coefficients of

Table 1. Demographics of participants who provided hair samples (n = 23).

Variable

N

%

Female

12

52%

Male

11

48%

Sex

Race/Ethnicity
Non-Hispanic White

12

52%

Asian/Pacific Islander

3

13%

Latino/Hispanic

7

30%

Other

1

4%

Some college

9

39%

Bachelors

9

39%

Graduate

5

22%

Education

Variable

N

Mean

SD

IQR

Age (in years)

23

34.2

9.0

26.6–41.1

Creatinine Clearance*

23

129.4

31.1

107.2–154.6

Weight (in kg)

23

73.9

13.2

64.1–86.3

*Estimated by the Cockcroft-Gault equation [57].
N = number of participants; SD = standard deviation; kg = kilograms. IQR = interquartile range.
doi:10.1371/journal.pone.0083736.t001
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Table 2. Median drug levels and geometric mean ratios in hair after 6 weeks of use, by dosing period.

Hair (scalp)
Dosing period

N

Median (range) TFV levels (ng/mg)

2 doses/week

22

0.012 (0.008 to 0.021)

4 doses/week

22

0.023 (0.011 to 0.042)

7 doses/week

21

0.038 (0.021 to 0.053)

Period comparison

Geometric mean ratios (95% CI)

4 vs. 2 doses/week

21

1.76 (1.45 to 2.13)

7 vs. 4 doses/week

21

1.60 (1.34 to 1.90)

7 vs. 2 doses/week

20

2.85 (2.46 to 3.32)

N = number; TFV = tenofovir; ng/mg = nanogram/milligram; CI = confidence interval.
doi:10.1371/journal.pone.0083736.t002

Allowing for different residual variance at different dose levels
(heteroscedasticity) resulted in similar dose and AUC estimates.
Also, similar results were observed when restricting analyses to the
7 doses/week period where intensive PK parameters were
measured (27% increase in hair level per 2-fold increase in
AUC, p = 0.042). Cmax appeared to have little positive effect on
hair level when controlled for dose and AUC (220% per 2-fold
increase, 95% CI 243% to +10%, p = 0.16). There was no
statistically significant effect of total body weight (p = 0.35),
estimated creatinine clearance (p = 0.52), or sex (p = 0.89) on
TFV hair concentrations.
Pubic hair TFV levels varied erratically and did not monotonically increase in 5/11 subjects who had at least two on-drug pubic
hair samples. In addition, levels were exceedingly high in 6
samples (,30–300 times higher than TFV levels in scalp hair).

Discussion
Accurate adherence measures are critical to the interpretation
of PrEP clinical trials and may play an important role in
monitoring PrEP use in clinical practice. An effective pharmacologic measure of PrEP adherence in a particular matrix must
demonstrate a clear relationship between dose and drug levels.
Our analysis provides evidence of a proportional relationship
between dose and hair levels of TFV in small samples of scalp hair
from healthy, HIV-uninfected individuals. Specifically, there was
an estimated 76% increase in TFV hair level with doubling of
dose, with similar dose effects across subjects. Hair concentrations
exhibited linearity with dose in the range of 2 to 7 doses per week,
with minimal inter-individual variation in dose effect. A hair
concentration of 0.021 ng/mg distinguished between 2 versus 7
doses/week dosing. This discrimination ability may have useful
clinical applications in monitoring PrEP use, as a previous PK
modeling study demonstrated that estimated protective efficacy for
taking FTC/TDF 2 doses/week was 76% (95% CI 56 to 96%),
compared with a projected 99% (95% CI 96 to .99%) for 7
doses/week [27]. There were 3/23 participants in which TFV
dose was not monotonically increasing. In all 3 cases, these
discrepancies were between 2 vs. 4 doses/week or 4 vs. 7 doses/
week.
Pubic hair samples were not useful in measuring TFV
concentrations and varied erratically in this study, with several
high outlier values. Similar results have been reported for pubic
hair levels of opiates [37], amphetamines [38], benzodiazepines
[39], and rodenticidal toxins [40], and may reflect urinary
contamination of pubic hair or the slower growth rate of pubic
hair. Furthermore, individual PK parameters, including oral
clearance as measured by plasma AUC, and Cmax, had modest
predictive value on drug levels in hair. The limited predictive value
of PK parameters in this study may have been due to withinperson variation over time in PK parameters (such that a single
PK measure may not completely represent systemic drug exposure
over the entire study period), or other factors that may influence
hair levels, such as differences in hair growth rate and drug in
sweat that came in contact with sampled hair [41].
Antiretroviral drug levels in hair have been shown to be highly
correlated with treatment outcomes in HIV-infected patients,
demonstrating stronger predictive value than self-reported adherence [22,24] or single plasma ARV concentrations [23,24].
Similarly, objective biological markers of PrEP adherence have
been used to predict protective efficacy in PrEP trials [2–4]. While
qualitative drug detection overall has demonstrated utility in

Figure 3. Spaghetti plot of tenofovir (TFV) concentrations. Hair
TFV concentrations for each subject are shown for each dosing period.
Each line represents drug concentration data from one participant (at 2,
4, and 7 doses/week). The red line distinguishes between hair scalp
concentrations for 2 vs. 7 doses/week. ng/mg = nanogram/milligram.
doi:10.1371/journal.pone.0083736.g003
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Table 3. Three participants where hair levels did not demonstrate monotonic increases.

Patient ID

Hair TFV (ng/mg) at 2 doses/week

Hair TFV (ng/mg) at 4 doses/week

Hair TFV (ng/mg)at 7 doses/week

039

0.017

0.011

0.044

051

0.013

0.028

0.026

063

0.012

0.042

0.028

ID = identification number; TFV = tenofovir; ng/mg = nanogram per milligram.
doi:10.1371/journal.pone.0083736.t003

useful in monitoring brief periods of PrEP use (e.g. preceding 2
weeks of PrEP use).
Our study had several strengths, including use of a randomized
cross-over study design, high adherence to mDOT procedures
ensuring dosing fidelity, and intensive PK sampling to evaluate key
PK parameters that could influence drug concentrations in various
compartments. This study also had several limitations. First,
participation was limited to individuals with dark hair, as we
aimed to reduce inter-individual variability and maximize the
ability of hair to discriminate between different adherence patterns
in this proof-of-concept study. While this may limit the generalizability of our findings, many PrEP studies are conducted in
international settings where most individuals have dark hair.
Second, oral clearance at steady state was only measured once
during the 7 doses/week period to reduce participant burden,
which did not allow for assessment of intra-subject variability at
the other dosing regimens. However, the predictive value of
plasma AUC on tenofovir hair levels did not substantially improve
in analyses predicting hair levels only after the 7 doses/week
period. Third, weekend or holiday doses were not directly
observed due to feasibility issues; however, these doses were
confirmed by text message or phone. This mDOT approach has
been demonstrated to be effective in prior studies [31,47]. Fourth,
likely due to our limited recruitment venues to facilitate DOT
dosing, we did not enroll African-American participants into this
proof-of-concept study. As African-Americans are disproportionately impacted by HIV [48] and are likely be a prioritized group
for PrEP, future studies evaluating the PK of TFV and FTC in
hair should include this important population. Another limitation
is that hair samples were only analyzed once, due to the limited
quantity of hair collected from subjects. Finally, this study
measured drug levels after 6 weeks of dosing, which may not
represent ‘‘steady state’’ concentrations in the proximal 1.5 cm of
hair due to growth rate variability. Additional studies are needed
to evaluate whether TFV levels in proximal hair samples continue
to increase with longer dosing periods (e.g. 3–6 months).
In summary, this study reports a consistent relationship between
tenofovir dose and hair in HIV-negative men and women. These
measures have already demonstrated utility for other ARVs in the
HIV treatment setting and the finding of a strong dose relationship
for tenofovir in hair paves the way for evaluation of its use in
monitoring adherence in tenofovir-based PrEP demonstration
projects and real-world PrEP settings. Unlike phlebotomy, hair
collection is inexpensive, noninvasive and does not require specific
skills, sterile equipment, or specialized storage conditions. While
this hair PK study collected 150–200 strands of hair, ,100 strands
are typically needed for TFV level analysis. Hair can be stored for
prolonged durations prior to analysis at room temperature and
shipped without biohazardous precautions or cold chain requirements. These features may make this monitoring tool particularly
promising in resource-poor settings, where high acceptability of
hair collection has been demonstrated [49–51]. While the current

predicting PrEP efficacy across a number of PrEP studies [42],
quantitative drug levels may provide further value in predicting
protective effects and could also be used in establishing potential
threshold drug levels for protection. For example, a regression
analysis in iPrEx estimated that a tenofovir-diphosphate (TFV-DP)
concentration of 16 femtomole (fmol)/106 PBMCs was associated
with a 90% reduction in HIV acquisition [27]. Similarly, women
in the CAPRISA study of 1% vaginal tenofovir gel who had a
tenofovir concentration of .1000 ng/mL in cervicovaginal fluid
samples had a significant reduction in HIV acquisition compared
with those on placebo, in contrast to women with tenofovir
concentrations of #1000 mg/mL, who did not [43]. Quantitative
drug levels can also be used to understand PrEP failures. In the
randomized phase of the iPrEx study, TFV-DP concentrations in
peripheral blood mononuclear cells was detected in only 3/42
HIV seroconverters at the visit with first evidence of HIV
infection, and quantitative TFV-DP levels were low (and below the
range expected for daily dosing) in these individuals at this time
point [27]. Finally, quantitative drug levels could be tested in realtime or near-time and be used to identify individuals who may
need additional adherence support while taking PrEP in upcoming
PrEP studies and demonstration projects. For example, having an
undetectable or low TFV hair drug level after PrEP initiation
could trigger further evaluation of patterns of adherence and/or
potential individual PK parameters affecting TFV clearance.
Patients with evidence of low adherence could receive a more
intensive adherence intervention and more frequent drug monitoring in PrEP implementation programs. Important next steps for
the use of hair as a biological marker of PrEP exposure will be to
establish the acceptability of hair collection in real-world PrEP
delivery settings, determine the relationship between hair and
PrEP efficacy in upcoming PrEP studies, assess the impact of
different dosing patterns (e.g. occasional missed doses vs. longer
drug holidays) on hair TFV levels, and evaluate the use of hair
levels in interpreting PrEP breakthrough infections. These data
will help determine whether analysis of hair drug levels could be
used as a primary monitoring tool of adherence in upcoming PrEP
studies and programs.
As tenofovir’s long intracellular half life could afford TDF-based
PrEP regimens some PK forgiveness [44], the protective effect of
PrEP is more likely to be affected by longer treatment
interruptions rather than occasional missed doses, a scenario
similar to missed doses to non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimens in HIV-infected individuals
with low to moderate adherence [45]. Strategies to improve the
utility of hair analyses to detect drug interruptions, such as
segmental hair analysis (analysis of short, contiguous segments of
hair from the scalp end) [46], warrant further investigation. Given
the consistent growth rate of hair in the occipital region of the
scalp at approximately 1 centimeter/month, analysis of shorter
segments of hair (e.g. proximal 0.5 cm of hair growth) may be
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equipment used for the LC-MS/MS method of hair analysis is
expensive, methods to analyze hair using thin layer chromatography (TLC), a simple and inexpensive analytical tool that has
been used to detect ARVs in human plasma, saliva, and umbilical
cord blood [52–54] are currently being developed or have been
developed [55] and may be performed by local laboratories in
resource-poor settings. A low-cost, point-of-care hair assay [55]
could also facilitate real or near-time testing of hair samples, and
results could be used to inform PrEP adherence counseling.
Quantitative, time-integrated measures of long-term drug
exposure in hair may provide more salient adherence information
than qualitative (e.g. detectable/undetectable) results or drug levels
in single plasma samples. Furthermore, our results may be useful
in interpreting data from intermittent PrEP trials. Such dose
reduction strategies are expected to lower costs and toxicity, but
would be difficult to evaluate without validated biomarkers of
adherence. Given that adherence is the ‘‘Achilles’ heel’’ of PrEP
[56], this novel biomarker examining drug levels in hair has the
potential to improve adherence measurement in PrEP trials,
implementation studies, PrEP adherence promotion strategies, and
real-world use.
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